Pharma sales buoy Novartis's second quarter, but earnings down 10%
This article was originally published in Scrip
Executive Summary
Sustained growth in pharmaceutical sales drove Novartis's second quarter net sales, but a stronger dollar caused earnings to fall by 10% to $2 billion. Basic EPS fell by 9% to $0.90.